§ 520.445

than 5 days; do not administer within 24 hours of slaughter.

[57 FR 37325, Aug. 18, 1992, as amended at 67 FR 78355, Dec. 24, 2002. Redesignated and amended at 76 FR 49649, Aug. 11, 2011; 78 FR 21059. Apr. 9, 2013]

§ 520.445 Chlortetracycline and sulfamethazine powder.

- (a) Specifications. Each pound of soluble powder contains chlortetracycline bisulfate equivalent to 102.4 grams (g) of chlortetracycline hydrochloride and sulfamethazine bisulfate equivalent to 102.4 g of sulfamethazine.
- (b) *Sponsor*. See No. 000010 in §510.600(c) of this chapter.
- (c) Related tolerances. See §§ 556.150 and 556.670 of this chapter.
- (d) Conditions of use in swine. Administer in drinking water as follows:
- (1) Amount. 250 milligrams (mg) of chlortetracycline and 250 mg of sulfamethazine per gallon.
- (2) Indications for use. For the prevention and treatment of bacterial enteritis; as an aid in the reduction of the incidence of cervical abscesses; and as an aid in the maintenance of weight gains in the presence of bacterial enteritis and atrophic rhinitis.
- (3) Limitations. Use as the sole source of chlortetracycline and sulfonamide. Not to be used for more than 28 consecutive days. Withdraw 15 days before slaughter.

[76 FR 49649, Aug. 11, 2011]

§ 520.446 Clindamycin capsules and tablets.

- (a) Specifications(1) Each capsule contains the equivalent of 25, 75, 150, or 300 milligrams (mg) clindamycin as the hydrochloride salt.
- (2) Each tablet contains the equivalent of 25, 75, or 150 mg clindamycin as the hydrochloride salt.
- (3) Each capsule contains the equivalent of 25, 75, or 150 mg clindamycin as the hydrochloride salt.
- (b) Sponsors. See sponsors in §510.600(c) of this chapter as follows:
- (1) Nos. 000009 and 000859 for use of capsules described in paragraph (a)(1) of this section.
- (2) No. 051311 for use of tablets described in paragraph (a)(2) of this section.

- (3) No. 043806 for use of tablets described in paragraph (a)(3) of this section.
- (c) Conditions of use in dogs(1) Amount. Wounds, abscesses, and dental infections: 2.5 to 15 mg per pound (/lb) body weight every 12 hours for a maximum of 28 days. Osteomyelitis: 5.0 to 15 mg/lb body weight every 12 hours for a minimum of 28 days.
- (2) Indications for use. For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus orintermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis. Prevotellamelaninogenicus. Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of aureus, B.fragilis, P. S. melaninogenicus, F. necrophorum, and C. perfringens.
- (3) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[67 FR 54954, Aug. 27, 2002, as amended at 68 FR 55824, Sept. 29, 2003; 69 FR 32273, June 9, 2004; 71 FR 39204, July 12, 2006; 73 FR 4077, Jan. 24, 2008; 78 FR 17596, Mar. 22, 2013]

§ 520.447 Clindamycin solution.

- (a) Specifications. Each milliliter of solution contains the equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.
- (b) *Sponsors*. See Nos. 000009, 000859, 051311, 058829, and 061623 in §510.600(c) of this chapter.
- (c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
- (d) Conditions of use(1) Dogs—(i) Amount. Wounds, abscesses, and dental infections: 2.5 to 15 mg per pound (/lb) body weight every 12 hours for a maximum of 28 days. Osteomyelitis: 5.0 to 15 mg/lb body weight every 12 hours for a minimum of 28 days.
- (ii) Indications for use. For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses

Food and Drug Administration, HHS

due to susceptible strains of Bacteroides fragilis, Prevotellamelaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens; dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens; and osteomyelitis due to susceptible strains of S. aureus, B.fragilis. melaninogenicus, F. necrophorum, and C. perfringens.

- (2) Cats—(i) *Amount*. 5.0 to 15.0 mg/lb body weight every 24 hours for a maximum of 14 days.
- (ii) Indications for use. For the treatment of skin infections (wounds and abscesses) due to susceptible strains of Staphylococcus aureus, S. intermedius, Streptococcus spp.; deep wounds and abscesses due to susceptible strains of Clostridium perfringens and Bacteroides fragilis; and dental infections due to susceptible strains of S. aureus, S. intermedius, Streptococcus spp., C. perfringens, and B. fragilis.

[67 FR 54954, Aug. 27, 2002, as amended at 67 FR 78684, Dec. 26, 2002; 68 FR 55824, Sept. 29, 2003; 69 FR 31734, June 7, 2004; 71 FR 39543, July 13, 2006; 72 FR 19796, Apr. 20, 2007; 78 FR 17596, Mar. 22, 2013; 78 FR 30197, May 22, 2013]

§ 520.452 Clenbuterol syrup.

- (a) Specifications. Each milliliter contains 72.5 micrograms of clenbuterol hydrochloride.
- (b) Sponsor. See 000010 in 510.600(c) of this chapter.
 - (c) [Reserved]
- (d) Conditions of use(1) Horses—(i) Amount. Administer orally twice a day (b.i.d.). Initial dose is 0.5 milliliter per 100 pounds body weight (0.8 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 1 milliliter per 100 pounds (1.6 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 1.5 milliliters per 100 pounds (2.4 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 2.0 milliliters per 100 pounds (3.2 micrograms per kilogram) for 3 days (6 treatments). If no improvement, horse is nonresponder to clenbuterol and treatment should be discontinued.
- (ii) Indications for use. Indicated for the management of horses affected with airway obstruction, such as oc-

curs in chronic obstructive pulmonary disease (COPD).

- (iii) Limitations. Treat at effective dose for 30 days. At the end of the 30day treatment period, drug should be withdrawn. If signs return, the 30-day treatment period may be repeated. If repeating treatment, the step-wise dosage schedule should be repeated. The effect of this drug on breeding stallions and brood mares has not been determined. Treatment starting with dosages higher than the initial dose is not recommended. Federal law prohibits the extralabel use of this drug in food animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
 - (2) [Reserved]

[63 FR 41419, Aug. 4, 1998]

§ 520.455 Clomipramine tablets.

- (a) Specifications. Each tablet contains 5, 20, 40, or 80 milligrams (mg) clomipramine hydrochloride.
- (b) Sponsor. See No. 058198 in $\S510.600$ (c) of this chapter.
- (c) Conditions of use(1) Amount. 2 to 4 milligrams of clomipramine hydrochloride per kilogram (0.9 to 1.8 milligrams per pound) of body weight per day, administered as a single daily dose or divided twice daily.
- (2) Indications for use. For use as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of
- (3) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

 $[64\ FR\ 1762,\ Jan.\ 12,\ 1999,\ as\ amended\ at\ 72\ FR\ 262,\ Jan.\ 4,\ 2007]$

§ 520.462 Clorsulon drench.

- (a) Specifications. The drug is a suspension containing 8.5 percent clorsulon (85 milligrams per milliliter).
- (b) *Sponsor*. See No. 050604 in §510.600(c) of this chapter.
- (c) Conditions of use. Cattle(1) Amount. One-quarter fluid ounce per 200 pounds of body weight (7 milligrams per kilogram or 3.2 milligrams per pound of body weight).
- (2) Indications for use. For the treatment of immature and adult liver fluke